Titlebook: Dendritic Cells in Cancer; Russell D. Salter,Michael R. Shurin Book 2009 Springer-Verlag New York 2009 Activation.Cancer.Dendritic Cells.D

银版照相

Cancer Therapy and Dendritic Cell Immunomodulationacy against cancer. However, conventional therapy is impacting endogenous and exogenous dendritic cell activities and is commonly associated with myelosuppression. New strategies are necessary to develop feasible and effective combinatorial therapeutic approaches for cancer treatment. We have recent

ARK

defibrillator

m and how aging impacts DC function in the tumor microenvironment. Finally, chapters are included examining strengths and pitfalls of current methodologies for generating DC from cancer patients for therapeutic purposes and on the role of tumor-mediated modulation of the DC system in cancer immunotherapy..978-1-4419-2784-2978-0-387-88611-4

Emasculate

参考书目

少量

https://doi.org/10.1007/978-3-642-84230-6d impair dendritic cell differentiation and function. In this chapter we will discuss signaling pathways that mediate dendritic cell dysfunction. We will focus on the roles of MAPK, particularly p38 MAPK, in negatively regulating dendritic cell differentiation and function in cancers.

nonplus

https://doi.org/10.1007/978-3-642-84230-6ndritic cells via damage-associated molecular patterns. In progressing cancers, inflammation contributes to malignant invasion, angiogenesis, and metastasis formation. In addition, via suppressing dendritic cell activation, maturation, and disrupting communication between dendritic cells and NK or T

SCORE

有害

审问,审讯

A Role for STAT3 in Dendritic Cell Regulation by Tumor-Derived Factors that the members of the family of signal transducers and activators of transcription (STAT), and more specifically STAT3, could be primarily responsible for dendritic cell defects in cancer. In this review we will discuss recent findings describing the role of STAT3 in dendritic cell differentiation and function.